America’s biopharmaceutical companies are committed to developing solutions to help diagnose, treat and prevent COVID-19. The biopharmaceutical industry is providing financial support and in-kind donations to organizations and collaborating with U.S. and global health authorities to combat this global public health emergency.
More than half of PhRMA members have R&D efforts under way or are providing donations of medicines and critical medical supplies as well as providing financial donations to support patients and first responders in addressing this evolving crisis.
More than half of PhRMA members have R&D efforts under way or are providing donations of medicines and critical medical supplies as well as providing financial donations to support patients and first responders in addressing this evolving crisis.
Our Commitment
Our Commitment to Beat Coronavirus
In these unprecedented times, we are coming together to achieve one shared goal: to beat COVID-19. The decades-long investments we have made in new technology, research and treatments have prepared us to act swiftly:
We are rapidly screening our vast global libraries of medicines to identify potential treatments and have numerous clinical trials underway to test new and existing therapies.
We are dedicating our top scientists and using our investments in new technologies to speed the development of safe and effective vaccines.
We are sharing the learnings from clinical trials in real time with governments and other companies to advance the development of additional therapies.
We are expanding our unique manufacturing
capabilities and sharing available capacity to
ramp up production once a successful medicine
or vaccine is developed.
We are collaborating with government agencies,
hospitals, doctors and others to donate supplies
and medicines to help those affected around
the world.
We are working with governments and insurers
to ensure that when new treatments and
vaccines are approved they will be available
and affordable for patients.
We all have unique roles to play and are confident that together we will be successful. And we won't rest until we are.
Updates/Alerts
Related
Related Resources
COVID-19 Vaccine Research and Development
As the COVID-19 pandemic continues to impact patients worldwide, America’s biopharmaceutical research companies are working around the clock with stakeholders across the research and development (R&D) ecosystem to advance vaccine candidates that will help prevent infection and stop the spread of the virus.
2020 Industry Profile Toolkit: The Biopharmaceutical Industry's Unique Role in Responding to COVID-19
As the outbreak of COVID-19 – a disease caused by a novel strain of coronavirus – evolves in the United States and around the globe, the biopharmaceutical industry is working around the clock to find solutions.
Working Together To Fight COVID-19: Vaccine Manufacturing Collaborations
Across the industry, biopharmaceutical companies are working around the clock to meet the demands of COVID-19 vaccine manufacturing. Even prior to knowing the efficacy of particular vaccine candidates, companies have proactively been increasing their own manufacturing capabilities as well as partnering with other manufacturers who are sharing available capacity to support production. These partnerships have been key to manufacturing ramp-up following vaccine authorization.
How Industry Collaboration and Partnerships are Supporting COVID-19 Vaccine Manufacturing
Across the industry, biopharmaceutical companies are working around the clock to meet the demands of COVID-19 manufacturing. To overcome hurdles in global vaccination efforts, biopharmaceutical companies have established partnerships to help support increased manufacturing output and speed up the ability to fight COVID-19 as distribution capacity is expanded around the globe.
Industry Commitment to Combating Coronavirus Print Ad
In these unprecedented times, America’s biopharmaceutical companies are coming together to achieve one shared goal: the eradication of COVID-19. The decades-long investments we made in new technology, research and treatments have prepared us to act swiftly.
Fighting Variants of COVID-19
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is working around the clock to develop and manufacture safe and effective vaccines. Across the industry, companies are further continuing clinical research to assess whether modifications or boosters are warranted to existing vaccines to address emerging variants.
